Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Author and article information

Contributors

Farida Ahangari: (View ORCID Profile)

Jonas C. Schupp: (View ORCID Profile)

Naftali Kaminski: (View ORCID Profile)

Journal

Title: American Journal of Respiratory and Critical Care Medicine

Abbreviated Title: Am J Respir Crit Care Med

Publisher: American Thoracic Society

ISSN (Print): 1073-449X

ISSN (Electronic): 1535-4970

Publication date (Electronic): August 23 2022

Affiliations

[1 ]Yale University School of Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, New Haven, Connecticut, United States;

[2 ]Icahn School of Medicine at Mount Sinai Department of Genetics and Genomic Sciences, Institute for Next Generation Healthcare,, New York, New York, United States

[3 ]Icahn School of Medicine at Mount Sinai Department of Medicine, Division of Clinical Immunology, New York, New York, United States

[4 ]National Jewish Health, Division of Pulmonary, Critical Care, and Sleep Medicine, Departments of Medicine, Pediatrics, and Immunology and Genomic Medicine, Denver, Colorado, United States

[5 ]Yale University School of Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, New Haven, Connecticut, United States

[6 ]University of Colorado, Division of Pulmonary Sciences and Critical Care Medicine; Departments of Medicine and Immunology and Microbiology, Denver, Colorado, United States

[7 ]Icahn School of Medicine at Mount Sinai Department of Genetics and Genomic Sciences, Institute for Next Generation Healthcare, New York, New York, United States

[8 ]Normandie University, Service de Pneumologie, CHU de Caen; UNICAEN, CEA, CNRS, ISTCT/CERVOxy Group, GIP CYCERON, Caen, France

[9 ]Yale University School of Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine, Departmnet of Medicine, New Haven, Connecticut, United States

[10 ]Arizona State University, ASU-Banner Neurodegenerative Disease Research Center, Tempe, Arizona, United States

[11 ]Section of Pharmacology, Otto Loewi Research Center, Medical University of Graz, Graz, Austria

[12 ]Yale University School of medicine , Section of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine , New Haven, Connecticut, United States

[13 ]AstaZero AB, Discovery Biology, Discovery Sciences, R&D,, Goteborg, Sweden

[14 ]AstaZero AB, BioPharmaceuticals R&D Cell Therapy, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, Goteborg, Sweden

[15 ]Baylor College of Medicine Department of Medicine, Houston, Texas, United States

[16 ]AstraZeneca, Emerging Innovations, Discovery Sciences, R&D, Boston, Massachusetts, United States

Article

DOI: 10.1164/rccm.202010-3832OC

PubMed ID: 35998281

SO-VID: 4c22e475-1b6b-47a7-a9df-d494cfc8025d

History

Data availability:

Comments

Comment on this article

scite_

Cited by 18

See all cited by